Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/05/23
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 08/03/23
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101GlobeNewsWire • 05/25/23
Dyne Therapeutics' Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual MeetingGlobeNewsWire • 05/17/23
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 05/11/23
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNSGlobeNewsWire • 05/02/23
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 03/23/23
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific ConferenceGlobeNewsWire • 03/20/23
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsGlobeNewsWire • 03/02/23
All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong BuyZacks Investment Research • 01/10/23
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect?Zacks Investment Research • 12/16/22
Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 12/09/22
Wall Street Analysts Predict a 141% Upside in Dyne Therapeutics, Inc. (DYN): Here's What You Should KnowZacks Investment Research • 11/30/22
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 11/03/22
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 10/31/22
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 CongressGlobeNewsWire • 10/11/22